A
24.66
0.29 (1.19%)
| Previous Close | 24.37 |
| Open | 24.63 |
| Volume | 999,110 |
| Avg. Volume (3M) | 1,809,930 |
| Market Cap | 3,095,224,576 |
| Price / Sales | 4.05 |
| Price / Book | 14.02 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Profit Margin | -25.33% |
| Operating Margin (TTM) | -12.31% |
| Diluted EPS (TTM) | -1.60 |
| Quarterly Revenue Growth (YOY) | 45.20% |
| Total Debt/Equity (MRQ) | 205.56% |
| Current Ratio (MRQ) | 4.25 |
| Operating Cash Flow (TTM) | -87.87 M |
| Levered Free Cash Flow (TTM) | -35.70 M |
| Return on Assets (TTM) | -12.32% |
| Return on Equity (TTM) | -93.55% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Apellis Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
0.7
| Analyst Consensus | 1.0 |
| Insider Activity | -1.0 |
| Price Volatility | 3.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.70 |
|
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 13.85% |
| % Held by Institutions | 103.47% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 57.00 (HC Wainwright & Co., 131.14%) | Buy |
| Median | 32.00 (29.77%) | |
| Low | 25.00 (RBC Capital, 1.38%) | Hold |
| Average | 39.40 (59.77%) | |
| Total | 2 Buy, 3 Hold | |
| Avg. Price @ Call | 24.26 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 04 Mar 2025 | 54.00 (118.98%) | Buy | 25.05 |
| Goldman Sachs | 03 Mar 2025 | 32.00 (29.76%) | Hold | 24.06 |
| HC Wainwright & Co. | 03 Mar 2025 | 57.00 (131.14%) | Buy | 24.06 |
| 13 Feb 2025 | 57.00 (131.14%) | Buy | 27.46 | |
| RBC Capital | 03 Mar 2025 | 25.00 (1.38%) | Hold | 24.06 |
| 29 Jan 2025 | 26.00 (5.43%) | Hold | 29.47 | |
| Wedbush | 03 Mar 2025 | 29.00 (17.60%) | Hold | 24.06 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| WATSON DAVID O. | 25.05 | 25.53 | -5,569 | -144,794 |
| Aggregate Net Quantity | -5,569 | |||
| Aggregate Net Value ($) | -144,794 | |||
| Aggregate Avg. Buy ($) | 25.05 | |||
| Aggregate Avg. Sell ($) | 25.53 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WATSON DAVID O. | Officer | 05 Mar 2025 | Sell (-) | 5,569 | 26.00 | 144,794 |
| WATSON DAVID O. | Officer | 04 Mar 2025 | Disposed (-) | 6,667 | 25.05 | 167,008 |
| WATSON DAVID O. | Officer | 04 Mar 2025 | Acquired (+) | 6,667 | 25.05 | 167,008 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |